Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin Treatment

S.M. Boekholdt, MD; F.M. Sacks, MD; J.W. Jukema, MD, PhD; J. Shepherd, MD; D.J. Freeman, PhD; A.D. McMahon, PhD; F. Cambien, MD; V. Nicaud, MA; G.J. de Grooth, MD, PhD; P.J. Talmud, PhD, DSc, FRCPath; S.E. Humphries, PhD, FRCPath, MRCP; G.J. Miller, MD, FRCP; G. Eiriksdottir, MSc; V. Gudnason, MD, PhD; H. Kauma, MD; S. Kakko, MD, PhD; M.J. Savolainen, MD, PhD; M. Arca, MD; A. Montali, BSc; S. Liu, MD; H.J. Lanz, MD; A.H. Zwinderman, PhD; J.A. Kuivenhoven, PhD, J.J.P. Kastelein, MD, PhD

[1]  K. Zerba,et al.  The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome , 2004 .

[2]  N. Samani,et al.  A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. , 2003, European heart journal.

[3]  F. Cambien,et al.  Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease. , 2003, Journal of the American College of Cardiology.

[4]  Thomas A Trikalinos,et al.  Genetic associations in large versus small studies: an empirical assessment , 2003, The Lancet.

[5]  D. Rader,et al.  Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[6]  A. Zwinderman,et al.  Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C-->A polymorphism and a novel promoter variant are independently associated with CETP concentration. , 2003, Human molecular genetics.

[7]  J. Brian Gray,et al.  Introduction to Linear Regression Analysis , 2002, Technometrics.

[8]  P. Ridker,et al.  A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. , 2002, Atherosclerosis.

[9]  A. Evans,et al.  A novel cholesteryl ester transfer protein promoter polymorphism (-971G/A) associated with plasma high-density lipoprotein cholesterol levels. Interaction with the TaqIB and -629C/A polymorphisms. , 2002, Atherosclerosis.

[10]  E. Hawe,et al.  Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle‐aged men , 2002, Annals of human genetics.

[11]  N. Yoshiike,et al.  Association of Human Cholesteryl Ester Transfer Protein-TaqI Polymorphisms with Serum HDL Cholesterol Levels in a Normolipemic Japanese Rural Population , 2002, Journal of epidemiology.

[12]  J. Ioannidis,et al.  Replication validity of genetic association studies , 2001, Nature Genetics.

[13]  A. Montali,et al.  Lack of association of the common TaqIB polymorphism in the cholesteryl ester transfer protein gene with angiographically assessed coronary atherosclerosis , 2001, Clinical genetics.

[14]  V. Gudnason,et al.  The -629C>A polymorphism in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men. , 2001, Atherosclerosis.

[15]  P. Barter,et al.  Cholesteryl ester transfer protein, high density lipoprotein and arterial disease , 2001, Current opinion in lipidology.

[16]  A. Rantala,et al.  Variation at the cholesteryl ester transfer protein gene in relation to plasma high density lipoproteins cholesterol levels and carotid intima‐media thickness , 2001, European journal of clinical investigation.

[17]  A. van Tol,et al.  Proatherogenic Role of Elevated CE Transfer From HDL to VLDL1 and Dense LDL in Type 2 Diabetes: Impact of the Degree of Triglyceridemia , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[18]  B. Nordestgaard,et al.  Common Cholesteryl Ester Transfer Protein Mutations, Decreased HDL Cholesterol, and Possible Decreased Risk of Ischemic Heart Disease: The Copenhagen City Heart Study , 2000, Circulation.

[19]  D. Corella,et al.  Association of TaqIB polymorphism in the cholesteryl ester transfer protein gene with plasma lipid levels in a healthy Spanish population. , 2000, Atherosclerosis.

[20]  L Tiret,et al.  Extensive association analysis between the CETP gene and coronary heart disease phenotypes reveals several putative functional polymorphisms and gene‐environment interaction , 2000, Genetic epidemiology.

[21]  P. Wilson,et al.  Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[22]  F. Cambien,et al.  New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[23]  C. Bouchard,et al.  Contribution of the cholesteryl ester transfer protein gene TaqIB polymorphism to the reduced plasma HDL-cholesterol levels found in abdominal obese men with the features of the insulin resistance syndrome , 1999, International Journal of Obesity.

[24]  V. Gudnason,et al.  Cholesteryl ester transfer protein gene effect on CETP activity and plasma high‐density lipoprotein in European populations , 1999, European journal of clinical investigation.

[25]  C. Packard,et al.  The effect of smoking on post‐heparin lipoprotein and hepatic lipase, cholesteryl ester transfer protein and lecithin:cholesterol acyl transferase activities in human plasma , 1998, European journal of clinical investigation.

[26]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[27]  J W Jukema,et al.  The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. , 1998, The New England journal of medicine.

[28]  A. Rantala,et al.  Sex difference in the regulation of plasma high density lipoprotein cholesterol by genetic and environmental factors , 1996, Human Genetics.

[29]  D. Arveiler,et al.  Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. , 1995, The Journal of clinical investigation.

[30]  A P Holmes,et al.  Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors. Associations between the TaqI B RFLP in the CETP gene and smoking and obesity. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[31]  C. Packard,et al.  Smoking and plasma lipoproteins in man: effects on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution , 1993, European journal of clinical investigation.

[32]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[33]  D. Erkelens,et al.  Elevated Cholesteryl Ester Transfer Protein Activity in IDDM Men Who Smoke: Possible Factor for Unfavorable Lipoprotein Profile , 1991, Diabetes Care.

[34]  R. Lawn,et al.  DNA polymorphism at the locus for human cholesteryl ester transfer protein (CETP) is associated with high density lipoprotein cholesterol and apolipoprotein levels , 1989, Clinical genetics.

[35]  R. Lawn,et al.  Multiple RFLPs at the human cholesteryl ester transfer protein (CETP) locus. , 1987, Nucleic acids research.

[36]  W. Kannel,et al.  Cigarette smoking and HDL cholesterol: the Framingham offspring study. , 1978, Atherosclerosis.

[37]  A. Tall.  Plasma lipid transfer proteins. , 1995, Annual Review of Biochemistry.